Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessMeasurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
-
Article
Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia
-
Article
Open AccessMRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received ...